Document Detail


Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis.
MedLine Citation:
PMID:  8477962     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We have previously shown in a 2-yr controlled trial that hypercholesterolemia, frequent in primary biliary cirrhosis, is lowered by ursodeoxycholic acid (13 to 15 mg daily). To further investigate this effect, we analyzed the influence of long-term ursodeoxycholic acid administration on serum lipids, lipoproteins and bile acids. The study involved a subgroup of 33 noncirrhotic patients (17 received ursodeoxycholic acid and 16 received a placebo) analyzed at inclusion and after 2 yr. The total serum cholesterol concentration was markedly reduced in the ursodeoxycholic acid-treated patients in comparison with the controls (mean +/- S.E.M. = 7.49 +/- 0.42 mmol/L and 7.07 +/- 0.23 mmol/L at entry and 4.44 +/- 0.40 mmol/L and 6.89 +/- 0.27 mmol/L at 2 yr in the ursodeoxycholic acid and placebo groups, respectively; p < 0.02). Quantitatively, this decrease was mainly caused by a fall in low-density-lipoprotein cholesterol, but very low density-lipoprotein cholesterol levels also fell significantly. High-density-lipoprotein cholesterol levels remained stable in both groups, but the high-density-lipoprotein2/high-density-lipoprotein3 cholesterol ratio fell significantly during ursodeoxycholic acid treatment. No significant change occurred in total triglyceride or total phospholipid levels. In the treated group, the proportion of ursodeoxycholic acid increased (up to 60% of total circulating bile acids), whereas that of cholic and chenodeoxycholic acids fell significantly. In conclusion, the cholesterol-lowering effect of ursodeoxycholic acid could be related to an improvement of cholestasis, modifications in cholesterol metabolism or both. Changes in endogenous bile acid composition induced by ursodeoxycholic acid might be the common denominator of these two mechanisms.
Authors:
R E Poupon; K Ouguerram; Y Chrétien; C Verneau; E Eschwège; T Magot; R Poupon
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Hepatology (Baltimore, Md.)     Volume:  17     ISSN:  0270-9139     ISO Abbreviation:  Hepatology     Publication Date:  1993 Apr 
Date Detail:
Created Date:  1993-05-25     Completed Date:  1993-05-25     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8302946     Medline TA:  Hepatology     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  577-82     Citation Subset:  IM    
Affiliation:
INSERM U21, Unité de Recherches Cliniques et Epidémiologiques, 94807 Villejuif, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticholesteremic Agents / therapeutic use*
Bile Acids and Salts / blood*
Cholesterol / blood*
Cholesterol, HDL / blood
Cholesterol, LDL / blood
Double-Blind Method
Follow-Up Studies
Humans
Liver Cirrhosis, Biliary / blood*,  drug therapy*
Liver Function Tests
Middle Aged
Placebos
Time Factors
Ursodeoxycholic Acid / therapeutic use*
Chemical
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Bile Acids and Salts; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Placebos; 128-13-2/Ursodeoxycholic Acid; 57-88-5/Cholesterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatit...
Next Document:  Compression of the common bile duct due to portal-vein thrombosis in polycythemia vera.